Premium
Guideline for the prevention of acute chemotherapy‐induced nausea and vomiting in pediatric cancer patients: A focused update
Author(s) -
Patel Priya,
Robinson Paula D.,
Thackray Jennifer,
Flank Jacqueline,
Holdsworth Mark T.,
Gibson Paul,
Orsey Andrea,
Portwine Carol,
Freedman Jason,
Madden Jennifer R.,
Phillips Robert,
Sung Lillian,
Dupuis L. Lee
Publication year - 2017
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26542
Subject(s) - aprepitant , palonosetron , medicine , guideline , chemotherapy induced nausea and vomiting , nausea , vomiting , intensive care medicine , chemotherapy , oncology , antiemetic , pathology
This update of the 2013 clinical practice guideline provides clinicians with guidance regarding the use of aprepitant and palonosetron for the prevention of acute chemotherapy‐induced nausea and vomiting (CINV) in children. The recommendations were based on three systematic reviews. Substantive changes were made to the guideline recommendations including the inclusion of palonosetron to the 5‐HT 3 antagonists recommended for children receiving highly emetogenic chemotherapy (HEC) and the recommendation of aprepitant for children 6 months of age or older receiving HEC. To optimize CINV control in children, future work must focus on closing critical research gaps.